ImmunoGen Gets Good News From Interim Analysis of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine (an antibody drug conjugate - ADC) as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification.